Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma
Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patient...
Gespeichert in:
Veröffentlicht in: | The Prostate 2001-10, Vol.49 (2), p.93-100 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 100 |
---|---|
container_issue | 2 |
container_start_page | 93 |
container_title | The Prostate |
container_volume | 49 |
creator | Szende, B. Romics, I. Minik, K. Szabó, J. Torda, I. Lovász, S. Szomor, L. Tóth, L. Bély, M. Kerényi, T. Bartók, K. Végh, A. |
description | Background
Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients.
Methods
At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression.
Results
Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease.
Conclusions
Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/pros.1122 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71216720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71216720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</originalsourceid><addsrcrecordid>eNp10E1P2zAYB3BrAq2F7bAvgHJhEofQx45jO0dUrYWpgq3bhLSL5ThPhCFNQpzw8u1x14iedrIPv-ftT8gXCucUgM3arvHnlDL2gUwpZDIG4OkBmQKTEHOayAk58v4eIGhgH8mE0lSxVMkpWa2xRdNjEeWuab1DH7k6widTDaZ3TR01ZdTfYWdaHHpnIyxLtP0_tJ3ah9LIms66utmYT-SwNJXHz-N7TP4svv2eX8arm-XV_GIVW04VixkoDrmQwBXwhIoiwUxKlSEtsjyXuU2RWSPCTwgBVOUUS1tkvBAGJcoiOSZfd33DCo8D-l5vnLdYVabGZvBaUkaFZBDg2Q7asKvvsNRt5zame9UU9DY6vT1Cb6ML9mRsOuQbLPZyzCqA0xEYb01Vdqa2zu8dB8kUV8HNdu7ZVfj6_4n6x_rm1zg63lU43-PLe4XpHrSQiUz17fVS36bp35-L9LueJ2_VG5Uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71216720</pqid></control><display><type>article</type><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</creator><creatorcontrib>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</creatorcontrib><description>Background
Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients.
Methods
At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression.
Results
Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease.
Conclusions
Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.1122</identifier><identifier>PMID: 11582587</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Age Factors ; Aged ; Androgen Antagonists - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Apoptosis - drug effects ; apoptotic and mitotic index ; bcl2 ; Biological and medical sciences ; Biopsy ; Carcinoma - drug therapy ; Carcinoma - pathology ; Humans ; Immunohistochemistry ; Ki-67 Antigen - biosynthesis ; Ki67 ; Male ; Medical sciences ; Mitotic Index ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; p53 ; prostate carcinoma ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Proto-Oncogene Proteins c-bcl-2 - biosynthesis ; Tumor Suppressor Protein p53 - biosynthesis ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2001-10, Vol.49 (2), p.93-100</ispartof><rights>Copyright © 2001 Wiley‐Liss, Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</citedby><cites>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.1122$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.1122$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14072848$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11582587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szende, B.</creatorcontrib><creatorcontrib>Romics, I.</creatorcontrib><creatorcontrib>Minik, K.</creatorcontrib><creatorcontrib>Szabó, J.</creatorcontrib><creatorcontrib>Torda, I.</creatorcontrib><creatorcontrib>Lovász, S.</creatorcontrib><creatorcontrib>Szomor, L.</creatorcontrib><creatorcontrib>Tóth, L.</creatorcontrib><creatorcontrib>Bély, M.</creatorcontrib><creatorcontrib>Kerényi, T.</creatorcontrib><creatorcontrib>Bartók, K.</creatorcontrib><creatorcontrib>Végh, A.</creatorcontrib><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Background
Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients.
Methods
At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression.
Results
Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease.
Conclusions
Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>apoptotic and mitotic index</subject><subject>bcl2</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen - biosynthesis</subject><subject>Ki67</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mitotic Index</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>p53</subject><subject>prostate carcinoma</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1P2zAYB3BrAq2F7bAvgHJhEofQx45jO0dUrYWpgq3bhLSL5ThPhCFNQpzw8u1x14iedrIPv-ftT8gXCucUgM3arvHnlDL2gUwpZDIG4OkBmQKTEHOayAk58v4eIGhgH8mE0lSxVMkpWa2xRdNjEeWuab1DH7k6widTDaZ3TR01ZdTfYWdaHHpnIyxLtP0_tJ3ah9LIms66utmYT-SwNJXHz-N7TP4svv2eX8arm-XV_GIVW04VixkoDrmQwBXwhIoiwUxKlSEtsjyXuU2RWSPCTwgBVOUUS1tkvBAGJcoiOSZfd33DCo8D-l5vnLdYVabGZvBaUkaFZBDg2Q7asKvvsNRt5zame9UU9DY6vT1Cb6ML9mRsOuQbLPZyzCqA0xEYb01Vdqa2zu8dB8kUV8HNdu7ZVfj6_4n6x_rm1zg63lU43-PLe4XpHrSQiUz17fVS36bp35-L9LueJ2_VG5Uw</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Szende, B.</creator><creator>Romics, I.</creator><creator>Minik, K.</creator><creator>Szabó, J.</creator><creator>Torda, I.</creator><creator>Lovász, S.</creator><creator>Szomor, L.</creator><creator>Tóth, L.</creator><creator>Bély, M.</creator><creator>Kerényi, T.</creator><creator>Bartók, K.</creator><creator>Végh, A.</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><author>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>apoptotic and mitotic index</topic><topic>bcl2</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen - biosynthesis</topic><topic>Ki67</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mitotic Index</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>p53</topic><topic>prostate carcinoma</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szende, B.</creatorcontrib><creatorcontrib>Romics, I.</creatorcontrib><creatorcontrib>Minik, K.</creatorcontrib><creatorcontrib>Szabó, J.</creatorcontrib><creatorcontrib>Torda, I.</creatorcontrib><creatorcontrib>Lovász, S.</creatorcontrib><creatorcontrib>Szomor, L.</creatorcontrib><creatorcontrib>Tóth, L.</creatorcontrib><creatorcontrib>Bély, M.</creatorcontrib><creatorcontrib>Kerényi, T.</creatorcontrib><creatorcontrib>Bartók, K.</creatorcontrib><creatorcontrib>Végh, A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szende, B.</au><au>Romics, I.</au><au>Minik, K.</au><au>Szabó, J.</au><au>Torda, I.</au><au>Lovász, S.</au><au>Szomor, L.</au><au>Tóth, L.</au><au>Bély, M.</au><au>Kerényi, T.</au><au>Bartók, K.</au><au>Végh, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>49</volume><issue>2</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>Background
Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients.
Methods
At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression.
Results
Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease.
Conclusions
Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>11582587</pmid><doi>10.1002/pros.1122</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-4137 |
ispartof | The Prostate, 2001-10, Vol.49 (2), p.93-100 |
issn | 0270-4137 1097-0045 |
language | eng |
recordid | cdi_proquest_miscellaneous_71216720 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Age Factors Aged Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Apoptosis - drug effects apoptotic and mitotic index bcl2 Biological and medical sciences Biopsy Carcinoma - drug therapy Carcinoma - pathology Humans Immunohistochemistry Ki-67 Antigen - biosynthesis Ki67 Male Medical sciences Mitotic Index Neoplasm Staging Nephrology. Urinary tract diseases p53 prostate carcinoma Prostate-Specific Antigen - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Proto-Oncogene Proteins c-bcl-2 - biosynthesis Tumor Suppressor Protein p53 - biosynthesis Tumors of the urinary system Urinary tract. Prostate gland |
title | Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20biopsies%20in%20evaluation%20of%20therapeutic%20effects%20in%20prostate%20carcinoma&rft.jtitle=The%20Prostate&rft.au=Szende,%20B.&rft.date=2001-10-01&rft.volume=49&rft.issue=2&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.1122&rft_dat=%3Cproquest_cross%3E71216720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71216720&rft_id=info:pmid/11582587&rfr_iscdi=true |